Lenvatinib Mesylate Intermediate CAS 15568-85-1 Mimọ> 97.0% (HPLC) Ile-iṣẹ
Ipese Kemikali Ruifu Lenvatinib Mesylate Intermediates Pẹlu Iwa mimọ to gaju
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Orukọ Kemikali | 5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion |
Awọn itumọ ọrọ sisọ | 5- (Methoxymethylene) Acid Meldrum;Cabozantinib Aimọ 56;Lenvatinib aimọ 79 |
Nọmba CAS | 15568-85-1 |
NỌMBA CAT | RF-PI1967 |
Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
Ilana molikula | C8H10O5 |
Òṣuwọn Molikula | 186.16 |
Ojuami Iyo | 132.0 ~ 134.0 ℃ |
iwuwo | 1,297 ± 0,06 g / cm3 |
Brand | Ruifu Kemikali |
Nkan | Awọn pato |
Ifarahan | Iyẹfun Odo |
1 H NMR julọ.Oniranran | Ni ibamu Pẹlu Be |
Mimọ / Analysis Ọna | > 97.0% (HPLC) |
Lapapọ Awọn Aimọ | <3.00% |
Igbeyewo Standard | Standard Enterprise |
Lilo | Agbedemeji ti Lenvatinib Mesylate (CAS: 857890-39-2) |
Package: Igo, apo bankanje aluminiomu, 25kg / Paali ilu, tabi gẹgẹ bi ibeere alabara
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS: 15568-85-1) jẹ agbedemeji ti Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib jẹ oogun akàn tairodu ti o ni idagbasoke nipasẹ Eisai Corporation of Japan (koodu: E7080), ti o jẹ ti oludena ti oral multi-receptor tyrosine kinase (RTK) ati pe o le ṣe idiwọ iṣẹ ṣiṣe kinase ti ifosiwewe idagbasoke endothelial ti iṣan (VEGF) Awọn olugba VEGFR1 (VEGF) FLT1), VEGFR2 (KDR), ati VEGFR3 (FLT4).Lenvatinib tun le dẹkun ilowosi ti awọn RTK miiran ni angiogenesis pathological, idagbasoke tumo, ati ilọsiwaju akàn ayafi fun awọn iṣẹ cellular deede wọn pẹlu fibroblast growth factor (FGF) awọn olugba FGFR1, 2, 3, ati 4;Olugba ifosiwewe idagbasoke ti platelet (PDGFR [alpha]), KIT, ati RET.[Awọn itọkasi]: Lenvatinib jẹ o dara fun itọju awọn alaisan ti akàn tairodu ti iṣipopada agbegbe tabi iru metastasis, iru ilọsiwaju ati ipanilara iodine-refractory differentiated type.Ni Oṣu Keji ọjọ 13, Ọdun 2015, US FDA fọwọsi oogun anticancer Lenvatinib fun itọju akàn tairodu.Lenvatinib jẹ inhibitor enzymu-pupọ-afojusun, ti o lagbara lati dena VEGFR2 ati VEGFR3 (igbasilẹ ifosiwewe idagbasoke endothelial ti iṣan).Orukọ iṣowo ti Lenvatinib jẹ Lenvima.Ni Oṣu Karun ọjọ 20, Ọdun 2015, Ile-iṣẹ Oogun Yuroopu (EMA) fọwọsi Lenvatinib fun itọju invasive, ilọsiwaju ti agbegbe tabi iyatọ metastatic (papillary, follicular, Iru Hurthle) akàn tairodu (DTC).Ninu idanwo naa, akoko iwalaaye agbedemeji fun awọn alaisan ti DTC ipanilara iodine-refractory ti a tọju pẹlu Lenvatinib jẹ oṣu 18 lakoko ti iye fun awọn alaisan ti o gba placebo jẹ oṣu 3 nikan.